9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Gefitinib in Treating Patients With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Gefitinib in Treating Patients With Malignant Mesothelioma

Gefitinib in Treating Patients With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Advanced Malignant Mesothelioma

Estimated Enrollment: 40

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Percentage of patients who remain failure-free,  Tumor response rate,  Toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0, Overall survival

Interventions: gefitinib, laboratory biomarker analysis

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: February 2006

Completion Date:

Last  Posted Date: January 17, 2013

Location: Cancer and Leukemia Group B, Chicago, Illinois, United States

Website Link: https://ClinicalTrials.gov/show/NCT00025207

Was this article helpful?
Dislike 0